Author: kodiac

  • Elinzanetant

    Dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist for non-hormonal treatment of menopausal vasomotor symptoms

    A non-hormonal, orally bioavailable dual NK1/NK3 receptor antagonist developed through GlaxoSmithKline, NeRRe Therapeutics, KaNDy Therapeutics, and Bayer for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, distinguished from selective NK3 antagonists by concurrent blockade of substance P signaling and consequent additive benefits on sleep, mood, and thermoregulatory dysregulation.

    Abstract

    Elinzanetant (Lynkuet; BAY3427080; formerly NT-814 and GSK1144814) is a potent and selective dual antagonist of the neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors, developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause and with endocrine therapy for hormone receptor-positive breast cancer. The compound received its first regulatory approval in the United Kingdom in July 2025, followed by approvals in Australia, Canada, Switzerland, and the United States, where it was approved by the Food and Drug Administration on October 24, 2025, under the trade name Lynkuet at a recommended dose of 120 mg orally once daily at bedtime. Elinzanetant is the first and only approved dual NK1/NK3 receptor antagonist, mechanistically distinct from fezolinetant (Veozah), which acts solely on the NK3 receptor. The dual mechanism targets kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus, where neurokinin B (NKB) acting through NK3 receptors initiates thermoregulatory dysregulation responsible for hot flashes, and substance P (SP) acting through NK1 receptors amplifies KNDy neuronal activity and contributes to sleep disruption, mood disturbance, and peripheral vasodilation. By antagonizing both receptor subtypes, elinzanetant addresses the composite symptom burden of menopause rather than isolated hot flash frequency alone. The compound exhibits high affinity for human NK1 receptors (pKi 8.7 to 10.2) and NK3 receptors (pKi 8.0 to 8.8), with greater than 300-fold selectivity for NK1 and greater than 100-fold selectivity for NK3 over off-target receptors. Pharmacokinetics are characterized by rapid oral absorption (median Tmax approximately 1 hour), absolute oral bioavailability of 52 percent, extensive plasma protein binding (99.7 percent), a large volume of distribution (137 L), and a long elimination half-life of approximately 45 hours that supports once-daily dosing. Metabolism is predominantly CYP3A4-mediated, producing three active metabolites with comparable NK1/NK3 potency at approximately 39 percent of parent plasma exposure. Excretion is predominantly fecal (90 percent as metabolites). The clinical evidence base comprises the OASIS Phase 3 program: OASIS 1 and OASIS 2 (12-week placebo-controlled studies in approximately 400 postmenopausal women each), OASIS 3 (52-week long-term study in 628 women), and OASIS 4 (12-week study in women receiving breast cancer endocrine therapy). All trials met primary endpoints, demonstrating statistically significant and clinically meaningful reductions in VMS frequency and severity at weeks 4 and 12, with onset of effect as early as week 1. Secondary endpoints showed significant improvements in sleep disturbances, menopause-related quality of life, and mood. Long-term efficacy was maintained through 52 weeks in OASIS 3 with no signal of hepatotoxicity, endometrial hyperplasia, or endometrial malignancy. The most common adverse events are headache (7.8 percent) and fatigue (5 percent). Elinzanetant is contraindicated in pregnancy, in severe hepatic impairment, and with concomitant strong CYP3A4 inhibitors. This monograph reviews the chemistry, synthesis, and stereochemistry of elinzanetant; the dual-receptor pharmacology in molecular and neurophysiological detail; the comprehensive human pharmacokinetic record; the clinical evidence base across the OASIS program and the dose-finding SWITCH-1 study; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations for research applications; the adverse-event and safety signal profile; and a comparative assessment of five alternative compounds for vasomotor symptom management against elinzanetant on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1627Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Trimetazidine

    Piperazine-derived partial fatty acid oxidation inhibitor (p-FOX) and metabolic modulator of myocardial energy substrate utilization

    A cytoprotective anti-ischemic piperazine developed by Laboratoires Servier as the first metabolic modulator of cardiac energy substrate preference, distinguished from hemodynamic antianginal agents by its oxygen-sparing shift from long-chain fatty acid beta-oxidation to glucose oxidation through selective inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

    Abstract

    Trimetazidine (1-(2,3,4-trimethoxybenzyl)piperazine) is a metabolic anti-ischemic agent developed by Laboratoires Servier in the late 1960s and first marketed in France in 1978 under the trade name Vastarel. It is registered in approximately 100 countries for the treatment of stable angina pectoris as add-on therapy to hemodynamic antianginal agents and, in certain jurisdictions, for symptomatic management of vertigo, tinnitus, and visual disturbance of vascular origin, although the European Medicines Agency restricted the latter indications following a 2012 Article 31 referral. The compound is not approved by the United States Food and Drug Administration and is not available in the United States, Canada, or the United Kingdom.

    The molecular mechanism of trimetazidine is metabolic rather than hemodynamic. The compound selectively inhibits the mitochondrial long-chain 3-ketoacyl coenzyme A thiolase (3-KAT, also designated mitochondrial trifunctional protein thiolase), the terminal enzyme in the beta-oxidation spiral of long-chain fatty acids, with an IC50 of approximately 75 nanomolar as originally reported by Kantor et al. (2000) in isolated working rat hearts, although subsequent work by MacInnes et al. (2003) using purified enzyme preparations challenged the direct enzymatic inhibition and proposed alternative upstream targets. The functional consequence of 3-KAT inhibition is a shift in myocardial energy substrate preference from fatty acid oxidation (which consumes more oxygen per mole of ATP generated) to glucose oxidation (which is approximately 12 percent more oxygen-efficient per unit of ATP), thereby preserving myocardial high-energy phosphate pools under ischemic conditions without altering heart rate, blood pressure, coronary blood flow, or rate-pressure product. The compound additionally increases pyruvate dehydrogenase activity, reduces intracellular calcium overload, attenuates reactive oxygen species generation, decreases neutrophil infiltration in ischemic myocardium, and preserves intracellular pH homeostasis during ischemia and reperfusion.

    The clinical evidence base for trimetazidine in stable angina pectoris is extensive. Multiple randomized controlled trials, including the TRIMPOL-I, TRIMPOL-II, and VASCO-angina studies, have demonstrated that trimetazidine as add-on therapy to beta-blockers, calcium channel blockers, or long-acting nitrates produces statistically significant improvements in total exercise duration, time to 1 mm ST-segment depression, and weekly angina attack frequency compared to placebo. The 2024 European Society of Cardiology guidelines for chronic coronary syndromes assign trimetazidine a Class IIb, Level of Evidence B recommendation as add-on antianginal therapy in patients with inadequate symptom control, a downgrade from the prior Class IIa designation that has been criticized by some experts as inconsistent with the available trial evidence. A separate and growing literature supports benefit in heart failure with reduced ejection fraction (HFrEF): multiple meta-analyses (Gao et al. 2011, Zhang et al. 2012, Weng et al. 2024) pooling data from over 1,500 patients have reported mean improvements in left ventricular ejection fraction of 6 to 7.5 percentage points, reductions in cardiac hospitalization (relative risk 0.43), and reductions in all-cause mortality (relative risk 0.47), leading to inclusion of trimetazidine in the 2021 ESC heart failure guidelines at a Class IIb level for relief of persistent angina in heart failure patients.

    Pharmacokinetics are characterized by rapid and near-complete gastrointestinal absorption, approximately 90 percent oral bioavailability, a plasma elimination half-life of approximately 6 hours for the immediate-release formulation (approximately 12 hours for the modified-release 35 mg formulation), renal elimination of approximately 60 percent of the administered dose as unchanged drug, and minimal hepatic cytochrome P450-mediated metabolism with low drug-drug interaction potential. The compound is generally well tolerated; the principal adverse events are gastrointestinal disturbance (nausea, epigastric discomfort), asthenia, headache, and dizziness. The most clinically significant safety signal is the induction of reversible parkinsonian symptoms (rest tremor, bradykinesia, gait disturbance, rigidity) in a small fraction of patients, predominantly elderly, on prolonged therapy. This signal prompted the 2012 EMA Article 31 referral that resulted in new contraindications (Parkinson disease, parkinsonian symptoms, tremor, restless leg syndrome, severe renal impairment) and restriction of indications. Symptoms resolve in most patients within weeks to months of drug discontinuation. This monograph reviews the chemistry, synthesis, and structural pharmacology of trimetazidine; the metabolic mechanism of action in molecular detail; the comprehensive pharmacokinetic profile; the clinical evidence base across angina, heart failure, and investigational indications; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; the adverse-event and safety signal record; and a structured comparative assessment of five alternative metabolic and antianginal agents against trimetazidine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1624Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Daridorexant

    Dual orexin receptor antagonist (DORA) with balanced OX1R and OX2R competitive antagonism

    A benzimidazole-triazole dual orexin receptor antagonist developed at Actelion and Idorsia Pharmaceuticals for the treatment of insomnia disorder, distinguished from earlier DORAs by an optimized pharmacokinetic profile yielding full-night sleep promotion with minimal next-morning residual impairment.

    Abstract

    Daridorexant (ACT-541468, marketed as Quviviq) is an orally administered, competitive dual orexin receptor antagonist (DORA) approved by the United States Food and Drug Administration in January 2022 and by the European Medicines Agency in April 2022 for the treatment of insomnia disorder in adults. The compound binds both the orexin type 1 receptor (OX1R) and orexin type 2 receptor (OX2R) at sub-nanomolar affinities (Ki 0.47 nM at OX1R, 0.93 nM at OX2R), producing competitive, reversible blockade of the wake-promoting orexin A and orexin B neuropeptides without direct engagement of GABAergic, histaminergic, monoaminergic, or opioid receptor systems. In a selectivity panel of more than 130 central and peripheral pharmacological targets, daridorexant demonstrated no significant off-target binding, a profile that distinguishes it from the benzodiazepines and the Z-drugs (zolpidem, zaleplon, eszopiclone) and that underpins a mechanism-based rationale for preservation of physiological sleep architecture, absence of rebound insomnia on discontinuation, and low liability for tolerance and physical dependence.

    The compound was discovered at Actelion Pharmaceuticals Ltd in Allschwil, Switzerland, under the leadership of Jean-Paul and Martine Clozel, and was selected from a large series of benzimidazole-containing dual orexin receptor antagonists on the basis of an optimized pharmacokinetic profile: a terminal elimination half-life of approximately 8 hours, oral bioavailability of 62 percent, rapid absorption (time to peak plasma concentration 1 to 2 hours), and a plasma clearance rate designed to provide full-night sleep coverage at a dose of 25 to 50 mg while minimizing next-morning residual sedation at efficacious doses. When Actelion was acquired by Johnson and Johnson in June 2017, the drug discovery operations (including daridorexant) were spun off into the newly created Idorsia Pharmaceuticals Ltd, which advanced the compound through Phase 2 and Phase 3 clinical development and secured regulatory approval.

    Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (Study 1, N=930; Study 2, N=924) conducted at 156 sites in 18 countries demonstrated statistically significant improvements in the co-primary endpoints of wake time after sleep onset (WASO) and latency to persistent sleep (LPS) measured by polysomnography at months 1 and 3. The 50 mg dose additionally improved patient-reported daytime functioning as measured by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), making daridorexant the first insomnia pharmacotherapy to demonstrate improvement on both nighttime sleep parameters and a validated daytime functioning instrument in a registration program. Sleep architecture analysis demonstrated preservation of rapid eye movement (REM) and non-REM sleep stage distributions, with no alteration of electroencephalographic spectral bands in N2, N3, or REM stages and no disruption of sleep spindle activity.

    Pharmacokinetics are dominated by hepatic CYP3A4-mediated metabolism, which accounts for approximately 89 percent of metabolic clearance. Protein binding is exceptionally high at 99.7 percent; volume of distribution at steady state is 31 liters; and systemic clearance is 5.0 liters per hour. Concomitant administration with strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) is contraindicated owing to a greater than 400 percent increase in daridorexant exposure; moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole) require dose reduction to 25 mg. The compound is classified as a Schedule IV controlled substance in the United States on the basis of human abuse potential data demonstrating dose-dependent drug-liking effects in recreational sedative drug users, consistent with the scheduling of the other approved DORAs suvorexant and lemborexant.

    The safety profile in pivotal trials and in a 40-week extension study (total treatment duration up to 12 months) demonstrated favorable tolerability. The most common adverse events were nasopharyngitis, headache, somnolence, and fatigue, occurring at low incidence. Adverse events of special interest (sleep paralysis, hypnagogic and hypnopompic hallucinations, cataplexy-like symptoms, suicidal ideation) were rare. No evidence of withdrawal symptoms, rebound insomnia, or tolerance was observed on abrupt discontinuation after up to 12 months of treatment. This monograph reviews the chemistry, synthesis, and structural pharmacology of daridorexant; the dual-receptor antagonist mechanism in molecular and functional detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology in rodent and canine models; the clinical evidence base from Phase 1 through Phase 3 and long-term extension; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal analysis; and a comparative assessment of five alternative insomnia pharmacotherapies against daridorexant on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1628Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • T3D-959

    Dual peroxisome proliferator-activated receptor delta/gamma (PPARd/g) agonist with primary PPARd selectivity and brain-penetrant insulin-sensitizing activity

    A non-thiazolidinedione dual nuclear receptor agonist originally developed for metabolic disease and repositioned as a first-in-class brain insulin-sensitizing therapy for Alzheimer’s disease, distinguished by concurrent PPARd and PPARg activation, high central nervous system penetrance, and Phase 2 evidence of disease-modifying effects on cognition and amyloid biomarkers.

    Abstract

    T3D-959 (DB-959, DB-959Na as the sodium salt) is an orally bioavailable, brain-penetrant, non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor delta (PPARd; human ED50 19 nM) and peroxisome proliferator-activated receptor gamma (PPARg; human ED50 297 nM), conferring approximately 15-fold selectivity for the delta isoform. The compound was originally synthesized by Bayer and advanced through Phase 1 clinical trials for dyslipidemia and type 2 diabetes by DARA BioSciences before being acquired in 2013 by T3D Therapeutics and repositioned as a disease-modifying candidate for Alzheimer’s disease (AD) on the basis of the “type 3 diabetes” hypothesis, which posits that sporadic AD is driven by progressive brain insulin resistance, deficient insulin and insulin-like growth factor signaling, and consequent neurometabolic dysfunction. T3D-959 is the first PPARd-activating compound to enter clinical development for AD and represents a mechanistically distinct approach from the anti-amyloid antibody and cholinesterase inhibitor classes that dominate the current AD therapeutic landscape. Preclinical characterization in the intracerebral streptozotocin (i.c. STZ) rat model of sporadic AD, conducted principally by the de la Monte laboratory at Brown University, demonstrated that oral T3D-959 at doses of 0.3 to 3.0 mg/kg/day preserved spatial learning and memory in the Morris water maze, prevented brain weight loss, normalized phosphorylated tau and amyloid precursor protein-amyloid beta 42 (AbPP-Ab42) levels, reduced markers of oxidative stress, and partially restored cholinergic enzyme expression and white matter integrity. Therapeutic effects were observed even when treatment was delayed seven days after the STZ insult, suggesting relevance to mild and moderate disease stages. A separate preclinical study demonstrated that T3D-959 at 1.0 mg/kg/day improved motor function and prevented cerebellar white matter atrophy in the same model. An exploratory Phase 2a clinical trial in 36 subjects with mild to moderate AD (Chamberlain et al. 2020) demonstrated safety and tolerability at oral doses of 3, 10, 30, and 90 mg daily for 14 days, with no serious adverse events. Pharmacokinetic analysis confirmed dose-dependent systemic exposure exceeding the PPARd ED50 at all doses tested. Plasma metabolomics showed dose-dependent reductions in branched-chain amino acids and ceramides and increases in acylcarnitines, consistent with improved insulin sensitivity and enhanced fatty acid beta-oxidation. FDG-PET neuroimaging demonstrated dose-dependent increases in regional cerebral glucose metabolism, with the strongest effects in the putamen, anterior cingulate, insula, and orbital frontal cortex. Cognitive assessments showed improvements on the ADAS-Cog11 at 30 mg and on the Digit Symbol Substitution Test at all doses, with a delayed improvement pattern consistent with a transcriptional regulatory mechanism of action and an apparent ApoE4 genotype interaction. The Phase 2 PIONEER trial, a 24-week multicenter randomized double-blind placebo-controlled study in 250 patients with mild to moderate AD, reported positive top-line results in November 2023 at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. In the modified intent-to-treat population (n=141), the 30 mg group showed improvement on ADAS-Cog11 (0.73 versus 2.70 on placebo; p=0.073), and the 15 mg group showed improvement on ADCS-CGIC (0.39 versus 0.86 on placebo; p=0.060). Plasma amyloid beta 42/40 ratio improved significantly in the 30 mg (p=0.011) and 45 mg (p=0.033) groups, and the neurodegeneration marker neurogranin improved significantly in the 30 mg group (p=0.035). The compound was well tolerated, with adverse event rates similar between active and placebo arms (37.3% versus 43.1%) and no treatment-related serious adverse events. A Phase 2b/3 trial (NCT06964230) at 30 mg daily for 78 weeks in approximately 376 patients with biomarker-validated mild to moderate AD is planned to initiate in 2026. T3D-959 is not approved for any indication in any jurisdiction. This monograph reviews the chemistry, dual-receptor pharmacology, preclinical evidence base, clinical development program, pharmacokinetics, sourcing, reconstitution, stack interactions, adverse-event signal, and a comparative assessment of five alternative PPAR-targeting and insulin-sensitizing candidates against T3D-959 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1635Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pelacarsen

    GalNAc3-conjugated 2′-MOE antisense oligonucleotide targeting apolipoprotein(a) mRNA for lipoprotein(a) reduction

    A hepatocyte-directed, triantennary N-acetylgalactosamine-conjugated antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis, designed to selectively reduce circulating lipoprotein(a) concentrations by RNase H1-mediated degradation of apolipoprotein(a) mRNA in hepatocytes, currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.

    Abstract

    Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle. The GalNAc3 conjugation exploits the high-density expression of the asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces to achieve rapid, selective uptake into the liver, the exclusive site of apo(a) biosynthesis, conferring a 20- to 30-fold improvement in potency relative to the unconjugated parent compound IONIS-APO(a)Rx and enabling clinically effective Lp(a) lowering at substantially reduced doses and extended dosing intervals.

    Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a) concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.

    In the pivotal Phase 2b dose-ranging trial (Tsimikas et al., 2020, New England Journal of Medicine), pelacarsen administered subcutaneously to 286 patients with established ASCVD and Lp(a) concentrations of 60 mg/dL or greater produced dose-dependent Lp(a) reductions of 35 to 80 percent across five dosing regimens (20 mg every 4 weeks, 40 mg every 4 weeks, 60 mg every 4 weeks, 20 mg every 2 weeks, and 20 mg every week) over 6 to 12 months, with the 20 mg weekly regimen achieving approximately 80 percent mean reduction. The compound was well tolerated; the principal adverse events were mild injection site reactions. On the basis of these results, the 80 mg monthly subcutaneous dose was selected for the Phase 3 cardiovascular outcomes program.

    The Lp(a)HORIZON trial (NCT04023552) is a randomized, double-blind, placebo-controlled Phase 3 study enrolling 8,323 patients with established cardiovascular disease and Lp(a) concentrations of 70 mg/dL or greater, designed to evaluate whether pelacarsen 80 mg administered subcutaneously once monthly reduces the incidence of major adverse cardiovascular events (MACE; composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) relative to placebo on a background of optimized standard-of-care therapy. Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase 3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, conjugation technology, and molecular pharmacology of pelacarsen; the comprehensive pharmacokinetic record including hepatic impairment and ethnic pharmacokinetic data; the preclinical and clinical evidence base; sourcing and handling considerations; stack interactions; adverse events and safety signal; and a comparative assessment of five Lp(a)-lowering agents against pelacarsen on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1625Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Efimosfermin

    Long-acting Fc-fusion fibroblast growth factor 21 (FGF21) analog with direct antifibrotic, anti-steatotic, and metabolic regulatory activity

    An engineered, once-monthly IgG1-Fc-fused FGF21 analog developed by Novartis and advanced through Boston Pharmaceuticals and GSK for the treatment of metabolic dysfunction-associated steatohepatitis, distinguished from other FGF21 analogs by a 21-day pharmacokinetic half-life that permits monthly subcutaneous dosing and by Phase 2 evidence of fibrosis reversal and MASH resolution in patients with moderate-to-advanced hepatic fibrosis.

    Abstract

    Efimosfermin alfa (formerly LLF580 under Novartis origination, subsequently designated BOS-580 under Boston Pharmaceuticals development, and now GSK-6519754 following acquisition by GSK plc) is a genetically engineered, long-acting analog of human fibroblast growth factor 21 (FGF21), a hepatokine and adipokine that regulates hepatic lipid oxidation, adipose tissue glucose uptake, triglyceride metabolism, and inflammatory signaling through formation of a ternary complex with the transmembrane tyrosine kinase FGF receptor 1c (FGFR1c) and the obligate co-receptor beta-klotho (KLB). The molecule is a homodimeric fusion protein in which two copies of a stabilized FGF21 variant are fused at their N-termini to the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). The FGF21 domain is further stabilized by the introduction of a non-native disulfide bond and point mutations that increase proteolytic resistance, together producing a pharmacokinetic half-life of approximately 21 days in humans and enabling subcutaneous administration once every four weeks. This dosing interval distinguishes efimosfermin from the weekly-dosed FGF21 analogs efruxifermin (Akero Therapeutics) and pegozafermin (89bio), which require subcutaneous injection every one to two weeks.

    The compound entered clinical development as LLF580 in a Novartis-sponsored Phase 1/2 trial (CLLF580X2102) in obese adults with modest hypertriglyceridemia, where 300 mg subcutaneously every four weeks for 12 weeks produced a 54 percent reduction in serum triglycerides, a 36 percent increase in HDL cholesterol, a 52 percent reduction in hepatic fat fraction by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), a 24 percent reduction in pro-peptide type III collagen (Pro-C3, a circulating fibrosis biomarker), and improvements in insulin sensitivity (38 percent reduction in fasting insulin, 29 percent reduction in C-peptide, and a 103 percent increase in adiponectin), all without significant body weight change. The compound was subsequently licensed to Boston Pharmaceuticals, renamed BOS-580, and advanced into a Phase 2a multicenter randomized double-blind placebo-controlled trial in participants with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), followed by a Phase 2b trial (NCT04880031) in 84 patients with biopsy-confirmed MASH and F2 or F3 fibrosis, where 300 mg once monthly for 24 weeks produced fibrosis improvement of at least one stage without MASH worsening in 45.2 percent of treated patients versus 20.6 percent on placebo (p = 0.038), MASH resolution without fibrosis worsening in 67.7 percent versus 29.4 percent on placebo (p < 0.01), and clinically meaningful improvements in glycemic control markers including glycated hemoglobin.

    In May 2025, GSK plc completed acquisition of efimosfermin from Boston Pharmaceuticals for 1.2 billion United States dollars upfront and up to 800 million dollars in milestone payments, with tiered royalties owed to Novartis Pharma AG. The compound has received United States Food and Drug Administration Breakthrough Therapy Designation and European Medicines Agency Priority Medicines (PRIME) Designation for the treatment of MASH. Phase 3 development (the ZENITH program) commenced in December 2025, with a potential first launch projected for 2029. GSK has indicated development plans in both MASH (including compensated cirrhosis) and alcohol-related liver disease (ALD), with potential for combination therapy with GSK’990, a complementary hepatology pipeline candidate. This monograph reviews the chemistry, molecular design, and receptor pharmacology of efimosfermin; the FGF21 signaling pathway; the comprehensive preclinical and clinical pharmacokinetic record; the clinical evidence base across Phase 1/2 and Phase 2 trials; the sourcing and quality considerations for this biologic investigational agent; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five FGF21-pathway therapeutic candidates against efimosfermin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1631Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Saroglitazar

    Dual peroxisome proliferator-activated receptor alpha/gamma (PPARalpha/gamma) agonist with predominant PPARalpha activity

    A first-in-class dual PPARalpha/gamma agonist developed by Zydus Cadila as the first new chemical entity discovered and approved in India, indicated for diabetic dyslipidemia and non-cirrhotic non-alcoholic steatohepatitis, and under clinical investigation for primary biliary cholangitis and metabolic dysfunction-associated steatotic liver disease in the United States.

    Abstract

    Saroglitazar, the magnesium salt of (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid, is a first-in-class dual agonist of peroxisome proliferator-activated receptors alpha and gamma (PPARalpha/gamma) with predominant PPARalpha and moderate PPARgamma activity. Developed by Zydus Cadila (now Zydus Lifesciences) under the development code ZYH1, it was the first new chemical entity discovered entirely in India to receive marketing authorization, granted in 2013 by the Drug Controller General of India for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not controlled by statins alone. In 2020, saroglitazar received a second indication in India for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH), making it the first drug approved anywhere in the world for that condition. The compound is marketed in India as Lipaglyn at an oral dose of 4 mg once daily and has subsequently received approval in Mexico.

    The dual PPARalpha/gamma mechanism provides a pharmacological profile that bridges the lipid-lowering activity of fibrates (PPARalpha agonists) with the insulin-sensitizing activity of thiazolidinediones (PPARgamma agonists) while avoiding the weight gain, edema, and cardiovascular risk signals that led to the withdrawal of earlier glitazar-class compounds (muraglitazar, tesaglitazar, ragaglitazar). PPARalpha activation increases hepatic fatty acid beta-oxidation, reduces triglyceride synthesis, and elevates high-density lipoprotein cholesterol. PPARgamma activation enhances peripheral insulin sensitivity in adipose and skeletal muscle tissue, reduces hepatic gluconeogenesis, and modulates adipokine secretion. The dual activation also provides anti-inflammatory and antifibrotic effects in the liver through suppression of nuclear factor kappa B signaling, reduction of pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin-6, interleukin-1 beta), and modulation of the leptin-to-adiponectin ratio.

    Pharmacokinetics in healthy human subjects are characterized by rapid oral absorption (median time to peak plasma concentration of 0.6 to 1.0 hours under fasting conditions), extensive plasma protein binding (approximately 96 percent), hepatic metabolism to saroglitazar sulfoxide and other metabolites, and a terminal elimination half-life of approximately 3 to 6 hours depending on sex and formulation. The compound does not accumulate on repeated once-daily dosing, and food does not meaningfully affect overall systemic exposure. The pharmacokinetic profile has been characterized in healthy volunteers, in patients with hepatic impairment (including cholestatic cirrhosis), and in patients with renal impairment.

    The clinical evidence base spans multiple Phase 2 and Phase 3 programs. The PRESS series of trials (PRESS I through PRESS VIII) established efficacy in diabetic dyslipidemia and hypertriglyceridemia, demonstrating non-inferiority to fenofibrate for triglyceride reduction and superiority to pioglitazone for lipid parameter improvement. The EVIDENCES series of trials evaluated saroglitazar in non-alcoholic fatty liver disease (NAFLD) and NASH, with the EVIDENCES II Phase 3 trial in India demonstrating significant histological improvement at 52 weeks. A US-based Phase 2 trial (Gawrieh et al. 2021) in 106 patients with biopsy-proven NASH demonstrated significant improvement in NAFLD activity score, liver enzymes, and lipid parameters at 16 weeks. In primary biliary cholangitis (PBC), the Phase 2 proof-of-concept study demonstrated a 49 to 51 percent reduction in alkaline phosphatase at 16 weeks in ursodeoxycholic acid-resistant or -intolerant patients, and the Phase IIb/III EPICS-III trial met its primary and secondary endpoints; regulatory submission to the United States Food and Drug Administration for this indication is anticipated in the first quarter of 2026. The compound has received orphan drug designation and Fast Track designation from the FDA for PBC.

    Saroglitazar is well tolerated at the 4 mg clinical dose. The principal adverse events are mild gastrointestinal complaints (dyspepsia, gastritis), asthenia, and pyrexia, with no clinically significant effects on body weight, hepatic transaminases, renal function, creatine phosphokinase, or cardiac parameters at doses up to 128 mg in single-dose safety studies. The absence of the thiazolidinedione-class adverse events (peripheral edema, weight gain, bone fracture, bladder cancer signal) is attributed to the predominant PPARalpha and moderate PPARgamma pharmacological balance. This monograph reviews the chemistry, synthesis, and stereochemistry of saroglitazar; the dual-receptor pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across diabetic dyslipidemia, NAFLD/NASH, PBC, and metabolic liver disease indications; reconstitution, sourcing, and handling considerations for laboratory work; stack-interaction implications; adverse-event and safety signals; and a comparative assessment of five alternative PPAR-targeting compounds against saroglitazar on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1634Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Levosimendan

    Calcium sensitizer with phosphodiesterase III inhibition and ATP-sensitive potassium channel activation

    A pyridazinone-dinitrile inodilator developed at Orion Corporation as a calcium-sensitizing positive inotrope for acutely decompensated heart failure, distinguished from conventional inotropes by its ability to enhance myocardial contractility without increasing intracellular calcium concentration or myocardial oxygen consumption, and by its long-lived active metabolite OR-1896 that sustains hemodynamic effects for days beyond infusion cessation.

    Abstract

    Levosimendan, the (R)-enantiomer of simendan, is a pyridazinone-derivative calcium sensitizer and positive inotropic agent developed by Orion Corporation (Finland) and approved in approximately 60 countries for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not considered adequate. The compound exerts its principal pharmacological effects through three complementary mechanisms: calcium-dependent binding to the N-terminal domain of cardiac troponin C, which stabilizes the calcium-troponin C interaction and enhances myofilament sensitivity to calcium without increasing intracellular calcium concentration; selective inhibition of phosphodiesterase III (PDE3) in cardiac and vascular smooth muscle, which elevates cyclic adenosine monophosphate and contributes to positive inotropy and vasodilation; and opening of ATP-sensitive potassium channels (both sarcolemmal and mitochondrial) in vascular smooth muscle and cardiomyocytes, producing peripheral and coronary vasodilation and conferring cardioprotective effects against ischemia-reperfusion injury. The composite pharmacology produces the characteristic inodilator profile: simultaneous enhancement of cardiac contractility, reduction of cardiac preload and afterload, and improvement in coronary perfusion, all achieved without a proportional increase in myocardial oxygen demand.

    The pharmacokinetic profile of levosimendan is distinguished by the formation of an active metabolite, OR-1896, through intestinal reduction of the parent compound to the amino-derivative OR-1855 followed by hepatic N-acetylation. OR-1896 exhibits calcium-sensitizing and PDE3-inhibitory activity comparable to the parent compound and possesses an elimination half-life of approximately 75 to 80 hours in heart failure patients, compared to approximately 1 hour for the parent. This metabolite formation pathway introduces N-acetyltransferase 2 (NAT2) acetylator phenotype as a determinant of OR-1896 exposure, with slow acetylators demonstrating lower OR-1896 concentrations and potentially diminished sustained hemodynamic effects. The prolonged activity of OR-1896 sustains hemodynamic improvement for 7 to 9 days following cessation of a standard 24-hour intravenous infusion, a property unique among clinically available inotropic agents.

    The clinical evidence base comprises six principal Phase II and Phase III randomized controlled trials (LIDO, RUSSLAN, CASINO, REVIVE-I, REVIVE-II, SURVIVE) enrolling more than 3,000 patients with acute decompensated heart failure, supplemented by extensive registry data, meta-analyses, and ongoing investigation in cardiac surgery, cardiogenic shock, septic cardiomyopathy, pulmonary hypertension, right ventricular failure, and advanced heart failure with intermittent ambulatory infusion protocols. The LIDO trial demonstrated hemodynamic superiority and a 31-day survival advantage over dobutamine. The SURVIVE trial, the largest randomized comparison (1,327 patients), demonstrated superior reduction in B-type natriuretic peptide but did not achieve the primary endpoint of reduced 180-day all-cause mortality compared to dobutamine, though subgroup analyses favored levosimendan in patients on chronic beta-blocker therapy and those with prior heart failure history. Levosimendan is marketed as Simdax (Orion Corporation) and is not approved by the United States Food and Drug Administration; the original new drug application was withdrawn in 1999 following a request for additional trials. This monograph reviews the chemistry and stereochemistry, the triple-mechanism molecular pharmacology, the unique metabolite-driven pharmacokinetic profile, the comprehensive clinical evidence base, sourcing considerations, reconstitution and handling, drug interactions, adverse events, and a comparative assessment against five alternative inotropic agents on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1623Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Tasimelteon

    Dual melatonin receptor agonist (MT1/MT2) with circadian rhythm entrainment activity

    A synthetic dihydrobenzofuran-cyclopropane melatonin receptor agonist developed at Bristol-Myers Squibb and advanced by Vanda Pharmaceuticals as the first FDA-approved pharmacotherapy for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and for nighttime sleep disturbances in Smith-Magenis Syndrome.

    Abstract

    Tasimelteon (VEC-162, BMS-214778) is an orally active, selective dual agonist of the melatonin MT1 and MT2 G-protein-coupled receptors, approved by the United States Food and Drug Administration for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals (January 2014) and for the treatment of nighttime sleep disturbances associated with Smith-Magenis Syndrome (December 2020). The compound is marketed by Vanda Pharmaceuticals under the trade name Hetlioz and was originally synthesized at Bristol-Myers Squibb as BMS-214778 before being licensed to Vanda in 2004 for clinical development. Tasimelteon is a circadian regulator that resets the master body clock in the suprachiasmatic nucleus of the hypothalamus by engaging both melatonin receptor subtypes, with approximately 2.1- to 4.4-fold greater affinity for the MT2 receptor (Ki approximately 0.07 to 0.17 nM) than for the MT1 receptor (Ki approximately 0.30 to 0.35 nM). The compound and its major metabolites have no appreciable affinity for more than 160 other pharmacologically relevant receptors, including gamma-aminobutyric acid, serotonin, noradrenaline, acetylcholine, dopamine, and opiate receptor systems, conferring a remarkably clean selectivity profile among circadian-active agents.

    The clinical evidence base for tasimelteon rests principally on two pivotal Phase 3 trials (SET and RESET), published in The Lancet in 2015, which demonstrated that 20 mg of oral tasimelteon administered nightly entrained the circadian pacemaker in totally blind individuals with Non-24 and that continued treatment was necessary to maintain entrainment. In the SET trial, tasimelteon achieved the co-primary endpoints of circadian entrainment of the melatonin rhythm and clinical response compared with placebo. In the RESET withdrawal trial, patients randomized to placebo after an entrainment run-in period showed significant deterioration in nighttime sleep, daytime sleep, and timing of sleep, while patients maintained on tasimelteon preserved their clinical benefit. A supplemental indication for Smith-Magenis Syndrome was approved in December 2020 based on a randomized, double-blind, placebo-controlled crossover study demonstrating improvement in nighttime sleep disturbances in both adults and children with this rare neurodevelopmental disorder characterized by an inverted circadian melatonin rhythm. A supplemental application for jet lag disorder has been twice rejected by the FDA (in 2019 and again in January 2026 upon re-review), despite court-ordered reconsideration by the DC Circuit Court of Appeals.

    Pharmacokinetics are characterized by rapid oral absorption (Tmax 0.5 to 3 hours), moderate oral bioavailability (approximately 38 percent), high plasma protein binding (approximately 90 percent), a short elimination half-life (1.3 hours), and extensive hepatic metabolism primarily through CYP1A2 and CYP3A4 oxidation pathways. The short half-life distinguishes tasimelteon from melatonin itself and from ramelteon and reflects the rapid clearance of the parent compound, with the chronobiotic effect being mediated by the timing of receptor occupancy rather than sustained plasma exposure. Eighty percent of an administered dose is recovered in urine as metabolites, with less than 1 percent excreted as unchanged parent compound. The five most abundant metabolites (M9, M11, M12, M13, M14) retain binding activity at the MT1 and MT2 receptors but at less than one-tenth the affinity of the parent compound. Clinically significant drug interactions include a 7-fold increase in exposure with fluvoxamine (a strong CYP1A2 inhibitor), a 90 percent decrease in exposure with rifampin (a strong CYP3A4 inducer), and an approximately 40 percent decrease in exposure in tobacco smokers (reflecting CYP1A2 induction). Elderly patients (older than 65 years) exhibit approximately 2-fold higher exposure than younger adults.

    This monograph reviews the chemistry, synthesis, and stereochemistry of tasimelteon; the dual melatonin receptor agonist pharmacology and circadian mechanism; the comprehensive human pharmacokinetic record including drug-drug interactions and special populations; the preclinical chronobiology; the clinical evidence base across Non-24, Smith-Magenis Syndrome, jet lag disorder, and insomnia indications; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five melatonin receptor agonists and related circadian agents (ramelteon, prolonged-release melatonin, agomelatine, suvorexant, and melatonin) against tasimelteon on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1629Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Resmetirom

    Liver-directed, beta-selective thyroid hormone receptor agonist (thyromimetic)

    A first-in-class, orally administered, hepatocyte-targeted partial agonist of thyroid hormone receptor beta developed by Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis, and the first pharmacotherapy approved by the United States Food and Drug Administration for this indication.

    Abstract

    Resmetirom (MGL-3196, VIA-3196; marketed as Rezdiffra) is a first-in-class, orally administered, small-molecule, liver-directed partial agonist of the thyroid hormone receptor beta (THR-beta) that received accelerated approval from the United States Food and Drug Administration on March 14, 2024, for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH) with moderate to advanced liver fibrosis (stages F2 to F3), in conjunction with diet and exercise. Resmetirom is distinguished from earlier thyromimetic compounds by approximately 28-fold functional selectivity for THR-beta over THR-alpha, hepatocyte-directed uptake mediated by organic anion transporting polypeptide 1B1 (OATP1B1), and a liver-to-plasma concentration ratio of approximately 8:1, properties that collectively minimize the extrahepatic thyrotoxic effects (tachycardia, bone loss, skeletal muscle wasting) that terminated development of prior thyroid hormone receptor agonists including eprotirome and sobetirome. The molecular mechanism involves activation of THR-beta in hepatocytes, promoting fatty acid beta-oxidation, mitochondrial biogenesis, mitophagy, and autophagy while inhibiting de novo lipogenesis; these effects reduce intrahepatic triglyceride accumulation and attenuate the inflammatory and fibrotic cascades characteristic of progressive steatohepatitis. In the pivotal Phase 3 MAESTRO-NASH trial (n = 888, biopsy-confirmed noncirrhotic MASH with F2 to F3 fibrosis), resmetirom at 100 mg daily achieved MASH resolution without fibrosis worsening in 36 percent of patients versus 13 percent on placebo at 52 weeks, and fibrosis improvement by at least one stage without worsening of MASH activity in 28 percent versus 15 percent on placebo, both co-primary endpoints reaching statistical significance. Secondary endpoints demonstrated reductions in low-density lipoprotein cholesterol (16.3 percent), apolipoprotein B (16.5 percent), and triglycerides (23.4 percent), consistent with the hepatic metabolic mechanism. Pharmacokinetics are characterized by oral absorption with a median time to peak concentration of approximately 4 hours, greater than 99 percent plasma protein binding, a median terminal half-life of 4.5 hours, metabolism predominantly through cytochrome P450 2C8 (CYP2C8), and elimination principally via feces (67 percent) with a minor renal component (24 percent). The principal adverse events are diarrhea and nausea, which are generally mild to moderate and self-limiting. Clinically significant drug interactions include inhibition of organic anion transporting polypeptide transporters (elevating statin exposures) and CYP2C8-mediated metabolic interactions. This monograph reviews the chemistry, synthesis, and structural pharmacology of resmetirom; the thyroid hormone receptor biology and mechanism of action in detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology; the clinical evidence base across the MAESTRO trial program; sourcing and quality verification for research-grade material; reconstitution and handling; stack-interaction considerations; adverse-event signal and safety profile; and a comparative assessment of five alternative MASH pharmacotherapy candidates against resmetirom on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1633Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.